TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01408160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04207723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Description: Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Description: Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg / day taken in the morning hours, per 12 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Paroxetine
Description: paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
Study: NCT00845572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consta Club
Description: Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
Study: NCT03516331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176 & FDL169 coadministration
Description: CFTR corrector and potentiator
Study: NCT03496532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard stimulation
Description: Fixed 70Hz pseudo-monophasic pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uniform distribution
Description: Uniform distribution 70Hz Biphasic pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poisson distribution
Description: Poisson distribution 70Hz Biphasic pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of LFP oscillations
Description: Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied.
Study: NCT03292133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
Study: NCT03708861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)
Description: Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)
Study: NCT03777787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Denatonium Benzoate
Description: A single intragastric administration of denatonium benzoate (1 µmol/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A single intragastric administration of water
Study: NCT03686800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivelin® plain patches
Description: The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
Study: NCT01447329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture
Description: Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Study: NCT03367286

Intervention type: OTHER
Intervention: inspection mode
Description: different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)

Intervention type: OTHER
Intervention: inspection mode
Description: different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
Study: NCT01405885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3605
Description: 0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3401
Description: 0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3605 AND INO-3609
Description: 0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3510
Description: 0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Influenza vaccine
Description: 0.5ml of vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study: NCT00240084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide (Natrecor(TM))
Description: administration of IV nesiritide
Study: NCT03493698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT00974857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCM
Description: Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
Study: NCT04002934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene Acetate
Description: 40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
Study: NCT03493698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir
Description: Inarigivir
Study: NCT04829838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous levetireacetam
Description: phenytoin is considered as control drug in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous levetireacetam
Description: phenytoin is considered as control drug in the study
Study: NCT03198988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smART Feeding Tube System
Description: Replacing generic feeding tube with smART Feeding Tube System.
Study: NCT03557437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT01995123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Smoking Education
Description: Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
Study: NCT04341818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and Vitamin D monthly
Description: For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
Study: NCT03296176

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample for metabolome analyse
Study: NCT04341818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and Vitamin D daily
Description: For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and no Vitamin D
Description: For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
Study: NCT03876756

Intervention type: OTHER
Intervention: postpartum acute urinary retention
Description: Collection of risk factors

Intervention type: OTHER
Intervention: no postpartum acute urinary retention
Description: Collection of risk factors
Study: NCT04261296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling +balneotherapy
Description: Both of these methods will be applied to patients in the third group.
Study: NCT01248312

Intervention type: DEVICE
Intervention: Sentec monitoring device
Description: Sentec monitor applied transcutaneously to forehead

Intervention type: DEVICE
Intervention: Sentec monitoring device
Description: Sentec monitor applied transcutaneously to forehead

Intervention type: DEVICE
Intervention: sentec monitor
Description: transcutaneous monitoring

Intervention type: DEVICE
Intervention: sentec monitor
Description: transcutaneous monitoring
Study: NCT04157634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prognostication model
Description: In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
Study: NCT00447187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
Study: NCT01995123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Smoking Cessation Therapy
Description: Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Therapy
Description: Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
Study: NCT03380962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
Study: NCT04458350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Promotions Group
Description: Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
Study: NCT00354874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol 50mcg
Description: salmeterol
Study: NCT01872169

Intervention type: OTHER
Group type: OTHER
Intervention: Disordered eating screening questionnaire
Study: NCT00848679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural lidocaine
Description: Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural lidocaine
Description: Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural lidocaine 2%
Description: 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural lidocaine 2%
Description: 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
Study: NCT00821418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseHaler treatment
Description: treatment is for two weeks, 3 times per day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP treatment (through a deactivated version of PulsHaler)
Description: treatment is for two weeks, 3 times per day
Study: NCT01352598

Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
Study: NCT04414982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Values Affirmation
Description: Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Values Affirmation
Description: Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
Study: NCT02653482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin matching placebo
Study: NCT02084966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Transplantation: OCT of Kidney Transplant
Description: Device: Optical Coherence Tomography of Kidney Transplant
Study: NCT03230916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL FDC
Description: IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Study: NCT02950246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perineural catheterization implementation
Description: Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural catheterization implementation
Description: Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidon iodine
Study: NCT01943201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new bedsheet
Description: sleeping 5 nights on the new bedsheet

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional bedsheet
Description: sleeping 5 nights on the conventional bedsheet
Study: NCT03386370

Intervention type: DEVICE
Group type: OTHER
Intervention: Indigo Mechanical Thrombectomy System
Description: Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra
Study: NCT01544868

Intervention type: OTHER
Group type: OTHER
Intervention: Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover
Description: Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
Study: NCT02795442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Even protein
Description: 5 day intake of even protein 3 day rotating menu.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skewed protein
Description: 5 day intake of skewed protein 3 day rotating menu.
Study: NCT04195503

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver Transplantation
Description: Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
Study: NCT02515136

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stimulus-response
Description: See summary
Study: NCT03296176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample for metabolome analyse

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample for metabolome analyse
Study: NCT01818245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study: NCT01257698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%-timolol 0.5% topical eyedrops
Description: Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
Study: NCT00328783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Breathing Coordinator (ABC)
Description: The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy